Finding the RAS–RAF–MEK–ERK (MAP kinase) signaling pathway and then targeting it has been a big step forward in treating advanced melanoma, especially when it comes to completely resected advanced‐stage melanoma therapy [95, 96]. Here, MAP2K7 is linked to melanoma.